APA (7th ed.) Citation

Neyns, B., Schwarze, J., Bertels, C., Geens, W., Tijtgat, J., Awada, G., . . . Duerinck, J. (2021). 342O Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial. Annals of Oncology, 32, S516. https://doi.org/10.1016/j.annonc.2021.08.006

Chicago Style (17th ed.) Citation

Neyns, B., et al. "342O Intracranial Administration of CTLA-4 and PD-1 Immune Checkpoint Blocking Monoclonal Antibodies in Recurrent Glioblastoma (rGB): A Multi-cohort Adaptive Phase I Clinical Trial." Annals of Oncology 32 (2021): S516. https://doi.org/10.1016/j.annonc.2021.08.006.

MLA (9th ed.) Citation

Neyns, B., et al. "342O Intracranial Administration of CTLA-4 and PD-1 Immune Checkpoint Blocking Monoclonal Antibodies in Recurrent Glioblastoma (rGB): A Multi-cohort Adaptive Phase I Clinical Trial." Annals of Oncology, vol. 32, 2021, p. S516, https://doi.org/10.1016/j.annonc.2021.08.006.